Abstract
Radiolabeled monoclonal antibodies have been used with encouraging results in conjunction with stem cell transplantation for patients with hematologic malignancies targeting a variety of surface antigens including CD33, CD45 and CD66 for leukemias, CD20 and CD22 for non-Hodgkin's lymphomas, and ferritin for Hodgkin's disease. The results obtained targeting epithelial antigens on solid tumors, however, have generally been less encouraging, primarily due to the relative insensitivity of these malignancies to ionizing radiation. In this report we review clinical studies that have incorporated myeloablative doses of targeted radiation using radiolabeled antibodies in conjunction with stem cell transplant regimens.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Press OW, Rasey J . Principles of radioimmunotherapy for hematologists and oncologists Semin Oncol 2000 27: 62 73
Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma New Engl J Med 1991 325: 1525 33
Dyer MJ, Kelsey SM, Mackay HJ et al. In vivo ‘purging’ of residual disease in CLL with Campath-1H Br J Haematol 1997 97: 669 672
Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion Blood 2000 96: 864 869
Horwitz SM, Breslin S, Negrin RS et al. Rituximab following high dose chemotherapy and autografting in B-cell non-Hodgkin's lymphoma (NHL): preliminary results of a phase I–II trial Proc Am Soc Clin Oncol 2000 19: 51a
Press OW . Physics for practitioners: the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma Semin Hematol 2000 37: 2 8
Press OW, Eary JF, Appelbaum FR et al. Radiolabeled antibody therapy of lymphomas. In: DeVita VT, Hellman S, Rosenberg SA (eds) Biologic Therapy of Cancer Updates V JB Lippincott Co: Philadelphia 1994 1 13
Press OW, Farr AG, Borroz KI et al. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies Cancer Res 1989 49: 4906 4912
Press OW, Howell-Clark J, Anderson S et al. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells Blood 1994 83: 1390 1397
Press OW, Shan D, Howell-Clark J et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells Cancer Res 1996 56: 2123 2129
Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens Blood 1990 76: 1867 1871
Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens Blood 1991 77: 1660 1665
Andrews RG, Takahashi M, Segal GM et al. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors Blood 1986 68: 1030 1035
Griffin JD, Linch D, Sabbath K et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells Leuk Res 1984 8: 521 534
Dinndorf PA, Andrews RG, Benjamin D et al. Expression of normal myeloid-associated antigens by acute leukemia cells Blood 1986 67: 1048 1053
Caron PC, Dumont L, Scheinberg DA . Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia Clin Cancer Res 1998 4: 1421 1428
Feldman E, Kalaycio M, Schulman P et al. Humanized monoclonal anti-CD33 antibody HuM195 in the treatment of relapsed/refractory acute myelogenous leukemia (AML): preliminary report of a phase II study Proc Am Soc Clin Oncol 1999 18: 4a
Appelbaum FR, Matthews DC, Eary JF et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia Transplantation 1992 54: 829 833
Jurcic JG, Caron PC, Nikula TK et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias Cancer Res 1995 55: 5908s 5910s
Jurcic JG, Divgi CR, McDevitt MR et al. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia Proc Am Soc Clin Oncol 2000 19: 8a
Hinman LM, Hamann PR, Wallace R et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics Cancer Res 1993 53: 3336 3342
Sievers EL, Appelbaum FR, Spielberger RT et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 1999 93: 3678 3684
Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 2001 19: 3244 3254
Omary MB, Trowbridge IS, Battifora HA . Human homologue of murine T200 glycoprotein J Exp Med 1980 152: 842 852
Andres TL, Kadin ME . Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia Am J Clin Pathol 1983 79: 546 552
Matthews DC, Appelbaum FR, Eary JF et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome Blood 1999 94: 1237 1247
Matthews DC, Appelbaum FR, Eary JF et al. 131I-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission Blood 1996 88: 142a
Ruffner KL, Matthews DC . Current uses of monoclonal antibodies in the treatment of acute leukemia Semin Oncol 2000 27: 531 539
Blaise D, Maraninchi D, Michallet M et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission Blood 2001 97: 3669 3371
Becker W, Goldenberg D, Wolf F . The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions Semin Nucl Med 1994 25: 1 13
Noworolska A, Harlozinska A, Richter R et al. Non-specific cross-reacting antigen (NCA) in individual maturation stages of myelocytic cell series Br J Cancer 1985 51: 371 377
Boccuni P, Di Noto R, Lo Pardo C et al. CD66c antigen expression is myeloid restricted in normal bone marrow but is a common feature of CD10+ early-B-cell malignancies Tissue Antigens 1998 52: 1 8
Bunjes D, Buchmann I, Duncker C et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I–II study Blood 2001 98: 565 572
Juweid M, Sharkey RM, Markowitz A et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody Cancer Res 1995 55: 5899s 5907s
Juweid ME, Stadtmauer E, Hajjar G et al. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma Clin Cancer Res 1999 5: 3292s 3303s
Knox SJ, Goris ML, Trisler K et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma Clin Cancer Res 1996 2: 457 470
Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Blood 2000 96: 1259 1266
Kaminski M, Zelenetz A, Press O et al. Multicenter phase III study of Iodine-131-tositumomab (anti-B1 antibody) for chemotherapy-refractory low grade or transformed low grade non-Hodgkin's lymphoma Blood 1998 92: 316a (Abstr.)
Press OW, Eary JF, Appelbaum FR et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support (see comments) New Engl J Med 1993 329: 1219 1224
Press OW, Eary JF, Appelbaum FR et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas Lancet 1995 346: 336 340
Liu SY, Eary JF, Petersdorf SH et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue J Clin Oncol 1998 16: 3270 3278
Press OW, Eary JF, Gooley T et al. A phase I/II trial of Iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B cell lymphomas Blood 2001 96: 2934 2942
Vose JM, Bierman PJ, Lynch JC et al. Radioimmunotherapy with Bexxar combined with high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (ASCT) for refractory non-Hodgkin's lymphoma (NHL): synergistic results with no added toxicity Proc Am Soc Clin Oncol 2001 20: 6a
Lenhard RE Jr, Order SE, Spunberg JJ et al. Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease J Clin Oncol 1985 3: 1296 1300
Vriesendorp HM, Herpst JM, Germack MA et al. Phase I–II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01 J Clin Oncol 1991 9: 918 928
Herpst JM, Klein JL, Leichner PK et al. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment J Clin Oncol 1995 13: 2394 2400
Bierman PJ, Vose JM, Leichner PK et al. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease J Clin Oncol 1993 11: 698 703
Appelbaum FR, Brown PA, Sandmaier BM et al. Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP Blood 1992 80: 1608 1613
Giralt S, Champlin R, Goodman M et al. Preliminary results of a phase I/II study of multiple myeloma (MM) patients treated with 166Holmium-DOTMP in combination with high dose melphalan +/− total body irradiation (TBI) with autologous stem cell transplant Blood 2000 96: 558a
Giralt S, Bensinger W, Wendt R III et al. Hemorrhagic cystitis after targeted radiotherapy with 166Holmium-DOTMP (166HO) for multiple myeloma (MM) is preventable with bladder irrigation Blood 2000 96: 391a
Tempero M, Leichner P, Dalrymple G et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial J Clin Oncol 1997 15: 1518 1528
Colcher D, Minelli MF, Roselli M et al. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies Cancer Res 1988 48: 4597 4603
Denardo SJ, O'Grady LF, Richman CM et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody Anticancer Res 1997 17: 1745 1751
Richman CM, DeNardo SJ, O'Grady LF et al. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions Cancer Res 1995 55: 5916s 5920s
Richman CM, DeNardo SJ, O'Grady LF et al. Fractionated intensive-dose radioimmunotherapy for breast cancer using I-131 chimeric (Ch) L6 with peripheral blood stem cell (PBSC) support and cyclosporin (CSA) Proc Am Soc Clin Oncol 1995 14: 322
Richman CM, DeNardo SJ . Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies Crit Rev Oncol Hematol 2001 38: 25 35
Juweid M, Neumann R, Paik C et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier Cancer Res 1992 52: 5144 5153
Baxter LT, Jain RK . Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution Microvasc Res 1991 41: 252 272
Fujimori K, Covell DG, Fletcher JE et al. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier J Nucl Med 1990 31: 1191 1198
Yokota T, Milenic DE, Whitlow M et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms Cancer Res 1992 52: 3402 3408
Hu S, Shively L, Raubitschek A et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts Cancer Res 1996 56: 3055 3061
King DJ, Turner A, Farnsworth AP et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments Cancer Res 1994 54: 6176 6185
Jurcic JG, McDevitt MR, Sgouros G et al. Phase I trial of targeted alpha-particle therapy for myeloid leukemias with bismuth-213-HuM195 (Anti-CD33) Proc Am Soc Clin Oncol 1999 18: 7a
Sgouros G, Ballangrud AM, Jurcic JG et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia J Nucl Med 1999 40: 1935 1946
McDevitt MR, Ma D, Lai LT et al. Tumor therapy with targeted atomic nanogenerators Science 2001 294: 1537 1540
McDevitt MR, Sgouros G, Finn RD et al. Radioimmunotherapy with alpha-emitting nuclides Eur J Nucl Med 1998 25: 1341 1351
Axworthy DB, Reno JM, Hylarides MD et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity Proc Natl Acad Sci USA 2000 97: 1802 1807
Press OW, Corcoran M, Subbiah K et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts Blood 2001 98: 2535 2543
Weiden PL, Breitz HB, Press O et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results Cancer Biother Radiopharm 2000 15: 15 29
Hall EJ . Cellular effects of ionizing radiation. In: Tubiana M, Dutreix J, Wambersie A (eds) Introduction to Radiobiology Taylor & Francis: London, UK 1990 86 125
Winter JN, Inwards D, Erwin W et al. Phase I trial combining 90Y zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL Blood 2001 98: 677a
Schrier DM, Stemmer SM, Johnson T et al. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial Cancer Res 1995 55: 5921s 5924s
Cagnoni PJ, Ceriani RL, Cole WC et al. Phase I study of high-dose radioimmunotherapy 90-Y-hu-BrE-3 followed by autologous stem cell support (ASCS) in patients with metastatic breast cancer Cancer Biother Radiopharma 1998 13: 328 (Abstr.)
Wong JYC, Somlo G, Odom-Maryon T et al. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 (cT84.66) anti-carcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with anti-carcinoembryonic antigen-producing metastatic breast cancer Clin Cancer Res 1999 5: 3224s 3231s
Richman CM, DeNardo SJ, O'Donnell RT et al. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibodies 170H.82 with autologous stem cell support and cyclosporin A Clin Cancer Res 1999 5: 3243s 3248s
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pagel, J., Matthews, D., Appelbaum, F. et al. The use of radioimmunoconjugates in stem cell transplantation. Bone Marrow Transplant 29, 807–816 (2002). https://doi.org/10.1038/sj.bmt.1703524
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703524
Keywords
This article is cited by
-
Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia
International Journal of Hematology (2008)
-
Radioimmunoconjugates in acute leukemia treatment: the future is radiant
Bone Marrow Transplantation (2005)
-
Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?
Bone Marrow Transplantation (2005)
-
Immunotherapy for acute myeloid leukemia
Current Oncology Reports (2005)
-
Antibody-targeted radiation cancer therapy
Nature Reviews Drug Discovery (2004)